Patrick Phillips

Generating author description...

All published works

Action	Title	Year	Authors
+	Comparison of methods for identifying the optimal treatment duration in trials for antibiotics	2024	Suzanne M. Dufault Brian Aldana Patrick Phillips
+ PDF Chat	Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial	2024	Isabelle R. Weir Suzanne M. Dufault Patrick Phillips
+ PDF Chat	A flexible multi‐metric Bayesian framework for decision‐making in Phase II multi‐arm multi‐stage studies	2023	Suzanne M. Dufault Angela M. Crook Katie Rolfe Patrick Phillips
+ PDF Chat	Estimands for clinical endpoints in Tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial	2023	Isabelle R. Weir Suzanne M. Dufault Patrick Phillips
+ PDF Chat	Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study	2023	Sunita Rehal Suzie Cro Patrick Phillips Katherine Fielding James R. Carpenter
+ PDF Chat	A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials	2023	Ekaterina V. Kurbatova Patrick Phillips Susan E. Dorman Erin Sizemore Kia Bryant Anne Purfield Jessica N. Ricaldi Nicole Brown John L. Johnson Carole L. Wallis
+	A Flexible Multi-Metric Bayesian Framework for Decision-Making in Phase II Multi-Arm Multi-Stage Studies	2023	Suzanne M. Dufault Angela M. Crook Katie Rolfe Patrick Phillips
+ PDF Chat	A comparison of clinical development pathways to advance tuberculosis regimen development	2022	Vincent Chang Patrick Phillips Marjorie Z. Imperial Payam Nahid Radojka M. Savić
+	Rethinking intercurrent events in defining estimands for tuberculosis trials	2022	Tra My Pham Conor Tweed James R. Carpenter Brennan C Kahan Andrew Nunn Angela M. Crook Hanif Esmail Ruth Goodall Patrick Phillips Ian R. White
+ PDF Chat	A comparison of clinical development pathways to advance tuberculosis regimen development	2022	Vincent Chang Patrick Phillips Marjorie Z. Imperial Payam Nahid Rada Savic
+	Noninferiority Trials	2022	Patrick Phillips David V. Glidden
+ PDF Chat	A systematic review of endpoint definitions in late phase tuberculosis therapeutic trials	2021	Nancy K. Hills Johnson Lyimo Payam Nahid Rada Savic Patrick Phillips
+	List of covariates in volume–outcome regression models	2021	Jonathan Michaels Emma Wilson Ravi Maheswaran Stephen Radley Georgina Jones Thaison Tong Eva Kaltenthaler Ahmed Aber Andrew Booth Helen Buckley Woods
+	Noninferiority Trials	2021	Patrick Phillips David V. Glidden
+	A systematic review of estimand and endpoint definitions in recent phase III trials in DS-TB and DR-TB: Preliminary Results	2020	Patrick Phillips
+ PDF Chat	Proposals on Kaplan–Meier plots in medical research and a survey of stakeholder views: KMunicate	2019	Tim P. Morris Christopher I Jarvis William J Cragg Patrick Phillips Babak Choodari‐Oskooei Matthew R. Sydes
+ PDF Chat	Rethinking non-inferiority: a practical trial design for optimising treatment duration	2018	Matteo Quartagno A. Sarah Walker James R. Carpenter Patrick Phillips Mahesh Parmar
+	Re-thinking non-inferiority: a practical trial design for optimising treatment duration	2018	Matteo Quartagno A. Sarah Walker James R. Carpenter Patrick Phillips Mahesh Parmar
+	Re-thinking non-inferiority: a practical trial design for optimising treatment duration	2018	Matteo Quartagno A. Sarah Walker James R. Carpenter Patrick Phillips Mahesh Parmar
+ PDF Chat	Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols	2017	Mahesh Parmar Matthew R. Sydes Fay Cafferty Babak Choodari‐Oskooei Ruth E. Langley Louise Brown Patrick Phillips Melissa Spears Sam Rowley Richard Kaplan
+ PDF Chat	INNOVATIVE CLINICAL TRIAL DESIGNS	2017	Patrick Phillips
+ PDF Chat	Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes	2016	Daniel J. Bratton Mahesh Parmar Patrick Phillips Babak Choodari‐Oskooei
+ PDF Chat	A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)	2016	Patrick Phillips Kelly E. Dooley Stephen H. Gillespie Norbert Heinrich Jason E. Stout Payam Nahid Andreas H. Diacon Rob E. Aarnoutse Gibson Kibiki Martin J. Boeree
+	Comments on ‘A modest proposal for dropping poor arms in clinical trials’ by Proschan and Dodd	2015	Daniel J. Bratton Babak Choodari‐Oskooei Patrick Phillips Matthew R. Sydes Mahesh Parmar
+	Adaptive clinical trials in tuberculosis: applications, challenges and solutions	2015	Geraint Davies Patrick Phillips Thomas Jaki
+ PDF Chat	A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis	2013	Daniel J. Bratton Patrick Phillips Mahesh Parmar
+ PDF Chat	Modifying the multi-arm multi-stage (MAMS) design for use in a phase II tuberculosis trial in sub-Saharan Africa with a time-to-event primary outcome	2013	Patrick Phillips Michael Höelscher Daniel J. Bratton Sunita Rehal Norbert Heinrich Georgette Plemper van Balen Andrew Nunn Rob Aarnoutse Sonja Henne Stephen H. Gillespie
+ PDF Chat	A multi-arm multi-stage design for binary outcomes and application to tuberculosis	2013	Daniel J. Bratton Patrick Phillips Mahesh Parmar
+ PDF Chat	Randomized clinical trials to identify optimal antibiotic treatment duration	2013	C. Robert Horsburgh Kimberly M. Shea Patrick Phillips Michael P. LaValley
+ PDF Chat	Reply to Dodd and Proschan	2012	Patrick Phillips Daniel J. Bratton Andrew Nunn Michael Höelscher
+	When inferiority meets non-inferiority: Implications for interim analyses	2012	Daniel J. Bratton Hywel C Williams Brennan C Kahan Patrick Phillips Andrew Nunn
+ PDF Chat	Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis	2012	Patrick Phillips Stephen H. Gillespie Martin J. Boeree Norbert Heinrich Rob E. Aarnoutse Timothy D. McHugh Michel Pletschette Christian Lienhardt Richard Hafner Charles S. Mgone
+ PDF Chat	The evolution of and challenges in defining the clinical endpoint in tuberculosis treatment trials with non-inferiority designs	2011	Patrick Phillips Angela M. Crook Andrew Nunn
+	Challenges of Phase III study design for trials of new drug regimens for the treatment of TB	2010	Patrick Phillips Andrew Nunn

Common Coauthors

Coauthor	Papers Together
Mahesh Parmar	8
Andrew Nunn	7
Daniel J. Bratton	7
James R. Carpenter	5
Suzanne M. Dufault	5
Payam Nahid	5
Babak Choodari‐Oskooei	4
Michael Höelscher	4
Angela M. Crook	4
Matteo Quartagno	3
Norbert Heinrich	3
Martin J. Boeree	3
Matthew R. Sydes	3
Stephen H. Gillespie	3
Sunita Rehal	2
Rada Savic	2
A. Sarah Walker	2
David V. Glidden	2
Isabelle R. Weir	2
Marjorie Z. Imperial	2
Brennan C Kahan	2
Vincent Chang	2
Katie Rolfe	2
Rob E. Aarnoutse	2
Gibson Kibiki	1
Nicholas D. James	1
Jason E. Stout	1
Ruth E. Langley	1
Hanif Esmail	1
Stephen Radley	1
Kimberly M. Shea	1
Anju Keetharuth	1
Phil Shackley	1
Andrew Booth	1
Hywel C Williams	1
Richard Hafner	1
Ziyaad Waja	1
Radojka M. Savić	1
Timothy D. McHugh	1
J. Chilcott	1
Justin Shenje	1
Sam Rowley	1
Sharlaa Badal‐Faesen	1
Ahmed Aber	1
Edward Goka	1
Fay Cafferty	1
Oksana Ocheretina	1
Munira Essat	1
Praveen Thokala	1
Stefan Goldberg	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis	2012	Patrick Phillips Stephen H. Gillespie Martin J. Boeree Norbert Heinrich Rob E. Aarnoutse Timothy D. McHugh Michel Pletschette Christian Lienhardt Richard Hafner Charles S. Mgone	6
+ PDF Chat	Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial	2009	Matthew R. Sydes Mahesh Parmar Nicholas D. James Noel W. Clarke David P. Dearnaley Malcolm D. Mason Rachel C. Morgan Karen Sanders Patrick Royston	6
+ PDF Chat	Speeding up the Evaluation of New Agents in Cancer	2008	Mahesh Parmar F. M.- S. Barthel Matthew R. Sydes Ruth E. Langley Richard Kaplan E. Eisenhauer Mark F. Brady Nicholas D. James Michael A. Bookman Ann Marie Swart	5
+ PDF Chat	Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit	2011	Patrick Royston Friederike M‐S Barthel Mahesh Parmar Babak Choodari‐Oskooei Valerie Isham	5
+	Reporting of Noninferiority and Equivalence Randomized Trials	2012	Gilda Piaggio Diana R Elbourne Stuart J. Pocock Stephen Evans Douglas G. Altman for the CONSORT Group	5
+ PDF Chat	Reporting of Noninferiority and Equivalence Randomized Trials	2006	Gilda Piaggio Diana R Elbourne Douglas G. Altman Stuart J. Pocock Stephen Evans	5
+	Bayesian Approaches to Randomized Trials	1994	David J. Spiegelhalter Laurence S. Freedman Mahesh Parmar	4
+ PDF Chat	Rethinking non-inferiority: a practical trial design for optimising treatment duration	2018	Matteo Quartagno A. Sarah Walker James R. Carpenter Patrick Phillips Mahesh Parmar	4
+	Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancer	2003	Patrick Royston Mahesh Parmar Wendi Qian	4
+	Per-Protocol Analyses of Pragmatic Trials	2017	Miguel A. Hernán James M. Robins	4
+	Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)	2015	Scott Evans Daniel B. Rubin Dean Follmann Gene Pennello W. Charles Huskins John H. Powers David Schoenfeld Christy Chuang‐Stein Sara E. Cosgrove Vance G. Fowler	3
+	Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics	2002	Ralph B. D’Agostino Joseph M. Massaro Lisa Sullivan	3
+ PDF Chat	Randomized clinical trials to identify optimal antibiotic treatment duration	2013	C. Robert Horsburgh Kimberly M. Shea Patrick Phillips Michael P. LaValley	3
+	Monitoring the ACTIVE-W trial: Some issues in monitoring a noninferiority trial	2007	John A. Cairns Janet Wittes D. George Wyse Janet Pogue Michael Gent Jack Hirsh John R. Marler Edward L.C. Pritchett	3
+ PDF Chat	Using simulation studies to evaluate statistical methods	2019	Tim P. Morris Ian R. White Michael J. Crowther	3
+	Rethinking intercurrent events in defining estimands for tuberculosis trials	2022	Tra My Pham Conor Tweed James R. Carpenter Brennan C Kahan Andrew Nunn Angela M. Crook Hanif Esmail Ruth Goodall Patrick Phillips Ian R. White	3
+ PDF Chat	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial	2012	Matthew R. Sydes Mahesh Parmar Malcolm D. Mason Noel W. Clarke Claire Amos John Anderson Johann S. de Bono David P. Dearnaley John Dwyer Charlene Green	3
+	The role of intention to treat in analysis of noninferiority studies	2007	Brian L. Wiens William W. Zhao	3
+ PDF Chat	Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome	2013	Babak Choodari‐Oskooei Mahesh Parmar Patrick Royston Jack Bowden	3
+ PDF Chat	A comparison of Bayesian adaptive randomization and multi‐stage designs for multi‐arm clinical trials	2014	James Wason Lorenzo Trippa	2
+	Data Monitoring Committees in Clinical Trials: A Practical Perspective	2002	Susan S. Ellenberg Thomas R. Fleming David L. DeMets	2
+	Assessing equivalence and noninferiority	2012	Jonathan Treadwell Stacey Uhl Kelley Tipton Tatyana Shamliyan Meera Viswanathan Nancy D Berkman Xin Sun Craig I Coleman Adam G. Elshaug Sonal Singh	2
+ PDF Chat	A modest proposal for dropping poor arms in clinical trials	2014	Michael A. Proschan Lori E. Dodd	2
+ PDF Chat	Including all individuals is not enough: Lessons for intention-to-treat analysis	2012	Ian R. White James R. Carpenter Nicholas J. Horton	2
+	Optimal design of multi‐arm multi‐stage trials	2012	James Wason Thomas Jaki	2
+ PDF Chat	A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection	2012	Dominic Magirr Thomas Jaki John Whitehead	2
+	When inferiority meets non-inferiority: Implications for interim analyses	2012	Daniel J. Bratton Hywel C Williams Brennan C Kahan Patrick Phillips Andrew Nunn	2
+	Some recommendations for multi-arm multi-stage trials	2012	James Wason Dominic Magirr Martin Law Thomas Jaki	2
+	Bayesian Design and Analysis of Active Control Clinical Trials	1999	Richard Simon	2
+ PDF Chat	Simulation methods to estimate design power: an overview for applied research	2011	Benjamin F. Arnold Daniel R Hogan John M. Colford Alan Hubbard	2
+	Some fundamental issues with non‐inferiority testing in active controlled trials	2002	Hung Hung Sue‐Jane Wang Yi Tsong John Lawrence Robert T. O'Neil	2
+	Interim futility analysis with intermediate endpoints	2008	Bryan Goldman Michael LeBlanc John Crowley	2
+	Sample Size Tables for Clinical Studies	2008	David Machin Michael J. Campbell Say Beng Tan Sze Huey Tan	2
+	Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non‐zero risk difference or non‐unity relative risk	1990	Paddy Farrington Godfrey Manning	2
+ PDF Chat	Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials	2013	Angela DeMichele Donald A. Berry JoAnne Zujewski Sally Hunsberger Larry Rubinstein Joseph E. Tomaszewski Gary Kelloff Jane Perlmutter Meredith Buxton Julia Lyandres	2
+	ESTABLISHING EQUIVALENCE BY SHOWING THAT A SPECIFIED PERCENTAGE OF THE EFFECT OF THE ACTIVE CONTROL OVER PLACEBO IS MAINTAINED	1999	Eric Holmgren	2
+	On Non-inferiority Analysis Based On Delta-method Confidence Intervals	2003	Mark Rothmann Hsiao‐Hui Tsou	2
+ PDF Chat	Bayesian statistics in medicine: a 25 year review	2006	Deborah Ashby	2
+	A Multiple Comparison Procedure for Comparing Several Treatments with a Control	1955	Charles W. Dunnett	2
+	Preservation of effect and the regulatory approval of new treatments on the basis of non‐inferiority trials	2007	Steven Snapinn Qi Jiang	2
+	Summarizing historical information on controls in clinical trials	2010	Beat Neuenschwander Gorana Capkun-Niggli Michael Branson David J. Spiegelhalter	2
+ PDF Chat	Multi-arm clinical trials with treatment selection: what can be gained and at what price?	2015	Thomas Jaki	2
+	Bayesian Design of Proof-of-Concept Trials	2014	Roland Fisch Ieuan Jones Julie Jones Jouni Kerman G. Rosenkranz Heinz Schmidli	2
+	Challenges in Implementing Adaptive Designs: Comments on the Viewpoints Expressed by Regulatory Statisticians	2006	Paul Gallo Willi Maurer	2
+ PDF Chat	Multi-Arm Clinical Trials of New Agents: Some Design Considerations	2008	Boris Freidlin Edward L. Korn Robert J. Gray Alison Martin	2
+	Considerations on covariates and endpoints in multi‐arm multi‐stage clinical trials selecting all promising treatments	2012	Thomas Jaki Dominic Magirr	2
+ PDF Chat	Trials to assess equivalence: the importance of rigorous methods	1996	Byron Jones Philip Jarvis John A. Lewis Alan Ebbutt	2
+	Discounting phase 2 results when planning phase 3 clinical trials	2012	Simon Kirby James R. Burke Christy Chuang‐Stein Chanthy Sin	2
+	Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality	2003	Mardi Gomberg‐Maitland Lars Frison Jonathan L. Halperin	2
+	I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy	2009	AD Barker C C Sigman Kelloff Gj NM Hylton DA Berry L. Esserman	2